Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Amrutanjan Health CareNSE:AMRUTANJAN -0.47%71 PB Ratio is 3.83 as of Sep. 15, 2026, which is 44% below its 10-year median of 6.86. GuruFocus rates NSE:AMRUTANJAN with a GF Score™ of 71/100 and a GF Value™ of ₹830.57 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 925 Drug Manufacturers companies, Amrutanjan Health Care ranks worse than 75.03% on this metric.
Amrutanjan Health Care Ltd stock PB Ratio (=3.83) is close to 10-year low of 3.83.
The historical rank and industry rank for Amrutanjan Health Care's PB Ratio or its related term are showing as below:
NSE:AMRUTANJAN'
s PB Ratio Range Over the Past 10 Years
Min: 3.83 Med: 6.86 Max: 11.98
Current: 3.83
During the past 13 years, Amrutanjan Health Care's highest PB Ratio was 11.98. The lowest was 3.83. And the median was 6.86.
NSE:AMRUTANJAN's PB Ratio is ranked worse than 75.03% of 925
companies
in the Drug Manufacturers industry
Industry Median: 1.97
vs NSE:AMRUTANJAN: 3.83
During the past 12 months, Amrutanjan Health Care's average Book Value Per Share Growth Rate was 13.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 8.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 10.30% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 14.90% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Amrutanjan Health Care was 60.40% per year. The lowest was -2.30% per year. And the median was 10.60% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Amrutanjan Health Care's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amrutanjan Health Care PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amrutanjan Health Care's PB Ratio distribution charts can be found below:
* The bar in red indicates where Amrutanjan Health Care's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Amrutanjan Health Care (NSE:AMRUTANJAN) has a PB Ratio of 3.83 as of Sep. 15, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Amrutanjan Health Care and its competitors. This is 44% below median its historical median of 6.86. Over the past decade, Amrutanjan Health Care's PB Ratio has ranged from 3.83 to 11.98. According to the industry distribution chart, Amrutanjan Health Care ranks #694 out of 925 companies in the Drug Manufacturers industry, placing it in the top 75%.
Is Amrutanjan Health Care's PB Ratio too high?
Amrutanjan Health Care's current PB Ratio of 3.83 is 44% below median its 10-year median of 6.86. Over the past 10 years, this metric has ranged from a low of 3.83 to a high of 11.98. The Drug Manufacturers industry median PB Ratio is 1.97. Amrutanjan Health Care's value of 3.83 is 94.4% above this industry median. Based on the distribution chart, Amrutanjan Health Care ranks #694 out of 925 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Amrutanjan Health Care has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Amrutanjan Health Care's PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Amrutanjan Health Care ranks #694 out of 925 companies for PB Ratio. This places Amrutanjan Health Care in the lower half of its industry. The industry median PB Ratio is 1.97. Amrutanjan Health Care's value of 3.83 is 94.4% above this benchmark. Historically, Amrutanjan Health Care's own PB Ratio has ranged from 3.83 to 11.98 over the past decade. While the company's 10-year median is 6.86 vs. the industry median of 1.97, Amrutanjan Health Care has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.97, based on 925 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amrutanjan Health Care's current PB Ratio of 3.83 is 94.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Amrutanjan Health Care and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amrutanjan Health Care's current PB Ratio is 3.83, which is 44% below median its own 10-year median of 6.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amrutanjan Health Care stock overvalued right now?
Based on GuruFocus' analysis, Amrutanjan Health Care (NSE:AMRUTANJAN) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹830.57, compared to a current price of ₹490.95 — trading 40.9% below its estimated fair value. The current PB Ratio is 3.83, which is 44% below median its 10-year median of 6.86 and 94.4% above the Drug Manufacturers industry median of 1.97. Amrutanjan Health Care's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Amrutanjan Health Care (NSE:AMRUTANJAN), the current PB Ratio is 3.83 as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amrutanjan Health Care (NSE:AMRUTANJAN) Overvalued in 2026?
Based on GuruFocus' analysis, Amrutanjan Health Care stock appears to be undervalued.
The current stock price of ₹490.95 is trading 40.9% below its estimated GF Value™ of ₹830.57.
GuruFocus considers Amrutanjan Health Care to be Significantly Undervalued.
Key valuation signals for NSE:AMRUTANJAN:
PB Ratio: 3.83 (44% below median its 10-year median of 6.86)
GF Value™: ₹830.57 vs. price of ₹490.95 (40.9% below fair value)
Industry Position: 94.4% above the Drug Manufacturers median (#694 of 925)
No single metric tells the full story. See the NSE:AMRUTANJAN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amrutanjan Health Care Ltd manufactures Ayurvedic and allopathic products. The company operates through the following segments: OTC Products, Beverages, and Others. The majority of the revenue is generated from its OTC segment which is engaged in the manufacturing products of pain management, congestion management, and hygiene. Its beverage segment includes manufacturing fruit juices and oral rehydration drinks. Some of its products include Roll-on, Spray, Balm, Cough Syrup, Sanitary napkins, and inhalers. Geographically, it generates the majority of the revenue from India.
71GF Score
Get the complete analysis for NSE:AMRUTANJAN
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AMRUTANJAN has been successfully added to your 
